Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or ...

Shares of weight-loss drugmakers Novo Nordisk and Eli Lilly rose on Tuesday after U.S. President Joe Biden proposed expanding ...

Stocks were higher Tuesday afternoon as investors digested earnings reports from several retailers and awaited results from ...

CMS proposes changes to Medicare and Medicaid to cover weight-loss drugs, recognizing obesity as a disease. This could expand ...

The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss medications received by RFK Jr.

And those who follow the Biden administration’s move to expand access to anti-obesity medications such as Ozempic and Wegovy, which are produced by the drugmaker Novo Nordisk, and Mounjaro and ...

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even ...

The good news is that HHS recognizes that vitally important anti-obesity medicines like Wegovy and Zepbound should be made available to all Americans, regardless of income. The bad news is that unless ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...